ACI-24-1801

• Research type

  Research Study

• Full title

  A Phase II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study to Assess the Safety, Tolerability, Immunogenicity and Target Engagement of ACI-24 Formulations in Patients with Mild Alzheimer’s Disease

• IRAS ID

  246134

• Contact name

  Julien Rongere

• Contact email

  julien.rongere@acimmune.com

• Sponsor organisation

  AC Immune SA

• Eudract number

  2018-000445-39

• Duration of Study in the UK

  3 years, 3 months, 31 days

• Research summary

  To assess the safety and tolerability of the ACI-24( study drug) formulations in patients with mild Alzheimer’s disease.

• REC name

  West Midlands - Coventry & Warwickshire Research Ethics Committee

• REC reference

  18/WM/0212

• Date of REC Opinion

  6 Aug 2018

• REC opinion

  Unfavourable Opinion